Integra LifeSciences Holdings Future Growth
Future criteria checks 3/6
Integra LifeSciences Holdings is forecast to grow earnings and revenue by 113.7% and 5.8% per annum respectively. EPS is expected to grow by 110.5% per annum. Return on equity is forecast to be 12.3% in 3 years.
Key information
113.7%
Earnings growth rate
110.5%
EPS growth rate
| Medical Equipment earnings growth | 16.4% |
| Revenue growth rate | 5.8% |
| Future return on equity | 12.3% |
| Analyst coverage | Good |
| Last updated | 13 Dec 2024 |
Recent future growth updates
Recent updates
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise
Nov 05
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Oct 24Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S
Sep 08Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Aug 21At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?
Jul 01Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Jun 21Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
May 28Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,787 | 99 | 251 | 267 | 9 |
| 12/31/2025 | 1,712 | 71 | 149 | 180 | 11 |
| 12/31/2024 | 1,613 | 1 | 73 | 153 | 11 |
| 9/30/2024 | 1,565 | -7 | 38 | 137 | N/A |
| 6/30/2024 | 1,567 | 24 | 59 | 142 | N/A |
| 3/31/2024 | 1,530 | 40 | 61 | 130 | N/A |
| 12/31/2023 | 1,542 | 68 | 73 | 140 | N/A |
| 9/30/2023 | 1,543 | 101 | 110 | 167 | N/A |
| 6/30/2023 | 1,545 | 131 | 155 | 208 | N/A |
| 3/31/2023 | 1,562 | 172 | 200 | 246 | N/A |
| 12/31/2022 | 1,558 | 181 | 217 | 264 | N/A |
| 9/30/2022 | 1,565 | 173 | 188 | 248 | N/A |
| 6/30/2022 | 1,567 | 166 | 205 | 263 | N/A |
| 3/31/2022 | 1,559 | 157 | 232 | 288 | N/A |
| 12/31/2021 | 1,542 | 169 | 264 | 312 | N/A |
| 9/30/2021 | 1,526 | 216 | 274 | 323 | N/A |
| 6/30/2021 | 1,509 | 206 | 262 | 310 | N/A |
| 3/31/2021 | 1,378 | 170 | 203 | 252 | N/A |
| 12/31/2020 | 1,372 | 134 | 140 | 204 | N/A |
| 9/30/2020 | 1,378 | 56 | 155 | 213 | N/A |
| 6/30/2020 | 1,387 | -3 | 78 | 207 | N/A |
| 3/31/2020 | 1,512 | 27 | 83 | 223 | N/A |
| 12/31/2019 | 1,518 | 50 | 97 | 231 | N/A |
| 9/30/2019 | 1,506 | 60 | 47 | 185 | N/A |
| 6/30/2019 | 1,493 | 101 | 124 | 200 | N/A |
| 3/31/2019 | 1,475 | 83 | 109 | 188 | N/A |
| 12/31/2018 | 1,472 | 61 | 122 | 200 | N/A |
| 9/30/2018 | 1,458 | 80 | 103 | 169 | N/A |
| 6/30/2018 | 1,371 | 70 | N/A | 135 | N/A |
| 3/31/2018 | 1,287 | 69 | N/A | 127 | N/A |
| 12/31/2017 | 1,188 | 65 | N/A | 115 | N/A |
| 9/30/2017 | 1,075 | 49 | N/A | 110 | N/A |
| 6/30/2017 | 1,047 | 66 | N/A | 111 | N/A |
| 3/31/2017 | 1,014 | 68 | N/A | 120 | N/A |
| 12/31/2016 | 992 | 75 | N/A | 116 | N/A |
| 9/30/2016 | 985 | 61 | N/A | 136 | N/A |
| 6/30/2016 | 958 | 9 | N/A | 108 | N/A |
| 3/31/2016 | 919 | 9 | N/A | 98 | N/A |
| 12/31/2015 | 883 | 7 | N/A | 105 | N/A |
| 9/30/2015 | 854 | 12 | N/A | 100 | N/A |
| 6/30/2015 | 827 | 53 | N/A | 111 | N/A |
| 3/31/2015 | 782 | 46 | N/A | 100 | N/A |
| 12/31/2014 | 797 | 36 | N/A | 84 | N/A |
| 9/30/2014 | 798 | 30 | N/A | 70 | N/A |
| 6/30/2014 | 814 | -10 | N/A | 70 | N/A |
| 3/31/2014 | 855 | -13 | N/A | 57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IART is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: IART is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IART is expected to become profitable in the next 3 years.
Revenue vs Market: IART's revenue (5.8% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: IART's revenue (5.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IART's Return on Equity is forecast to be low in 3 years time (12.3%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 17:32 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Integra LifeSciences Holdings Corporation is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Matthew Taylor | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |